Kishore Arcot, MD
Cardiovascular Disease · Memphis, TNNPI 1841267846
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,775 of the $8,605 with a category attached, or 78.7%. 35 manufacturers reported payments, led by Medtronic at 35.3% of the total. Reporting peaked in 2022 at $3,097 and has fallen 77.1% since, to $708 in 2025.
Across 407 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Johnson & Johnson$955
- Cardiovascular Systems Inc.$924
- AstraZeneca$522
- Tactile Systems Technology Inc$439
- Novartis$432
- plus $2K from 29 others
Across 9 payments — averaging $12,813 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$115K
What the payments were for
- Travel & lodging$1,76821%
- Food & beverage$6,77579%
- Education$621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 107 | $3,035 |
| Johnson & Johnson | 60 | $955 |
| Cardiovascular Systems Inc. | 13 | $924 |
| AstraZeneca | 33 | $522 |
| Tactile Systems Technology Inc | 24 | $439 |
| Novartis | 27 | $432 |
| Abbott | 26 | $409 |
| E.r. Squibb & Sons, L.L.C. | 16 | $299 |
| Bard Peripheral Vascular, Inc. | 25 | $277 |
| Boehringer Ingelheim | 15 | $239 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $191 |
| Boston Scientific | 6 | $148 |
| Bayer | 3 | $119 |
| Pfizer | 5 | $78 |
| Biotronik Inc. | 4 | $64 |
| Astellas Pharma US Inc | 3 | $60 |
| Cvrx, Inc. | 3 | $38 |
| Sanofi | 1 | $33 |
| Philips North America LLC | 2 | $32 |
| Actelion Pharmaceuticals US, Inc. | 3 | $31 |
| Abiomed | 1 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Venclose Inc. | 4 | $27 |
| Baxter Healthcare | 1 | $23 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $20 |
| Avinger Inc. | 1 | $19 |
| Amgen | 1 | $19 |
| Angiodynamics, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Cashflow Solutions, LLC | 1 | $17 |
| Novo Nordisk | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $13 |
| Galderma Laboratories, L.p. | 1 | $12 |
| Biosense Webster, Inc. | 1 | $12 |
| Smith+Nephew | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,120
- Diamondback Peripheral$788
- SYMPLICITY G3$329
- Resolute$142
- ONYX FRONTIER$128
How this compares
$8,605 in reported general payments places this provider in the 80th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 153 | $151,713 |
| EntrestoSacubitril/Valsartan | 96 | $104,896 |
| XareltoRivaroxaban | 61 | $71,788 |
| BrilintaTicagrelor | 53 | $31,372 |
| JardianceEmpagliflozin | 22 | $14,960 |
| Nebivolol Hcl | 76 | $4,056 |
| Carvedilol | 416 | $3,539 |
| Losartan Potassium | 216 | $2,123 |
| Amlodipine Besylate | 287 | $1,758 |
| Atorvastatin Calcium | 163 | $1,637 |
| Potassium Chloride | 122 | $1,553 |
| ClopidogrelClopidogrel Bisulfate | 114 | $1,493 |
| Amiodarone Hcl | 37 | $1,067 |
| Hydralazine Hcl | 74 | $1,065 |
| Rosuvastatin Calcium | 65 | $983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $78 | $151,713153 claims |
| NovartisEntresto | $432 | $104,89696 claims |
| Johnson & JohnsonXarelto | $955 | $71,78861 claims |
| AstraZenecaBrilinta | $522 | $31,37253 claims |
| Boehringer IngelheimJardiance | $239 | $14,96022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Memphis
- Steven GubinMemphis$248K
- Frank McGrewMemphis$119K
- Ritin BombMemphis$16K
- Arie SzatkowskiMemphis$13K
- William AitkenMemphis$12K
- David MetzgerKingsport$555K
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.